Product image of Isovurex (Ezetimibe) supplied by GNH India

Isovurex

Active Ingredient:
Ezetimibe
Origin:
EU

Isovurex (Ezetimibe)

Ezetimibe, the active ingredient in Isovurex, is a cholesterol absorption inhibitor presented as an oral tablet for oral administration. It reduces elevated low‑density lipoprotein cholesterol in adults with primary hyperlipidemia, heterozygous or homozygous familial hypercholesterolemia, and related lipid disorders.

GNH India supplies Isovurex as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with distribution across EU and other markets, and the company adheres to stringent quality standards and provides regulatory support for importers and healthcare providers globally.

Manufacturer / TM Owner

Msn Labs Europe Limited

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Ezetimibe is used to lower cholesterol by inhibiting intestinal absorption, and is indicated for several lipid disorders.
  • Hypercholesterolemia: reduces LDL‑C levels in patients with elevated cholesterol.
  • Heterozygous familial hypercholesterolemia: lowers LDL‑C in individuals with a single defective LDLR gene.
  • Homozygous familial hypercholesterolemia: provides cholesterol reduction in patients with two defective LDLR genes.
  • Primary hyperlipidemia: improves overall lipid profile in adults with elevated triglycerides and cholesterol.

How It Works

  • Ezetimibe selectively blocks the Niemann‑Pick C1‑like 1 (NPC1L1) transporter on the brush‑border of enterocytes, preventing the uptake of dietary and biliary cholesterol. This reduces the amount of cholesterol delivered to the liver, prompting up‑regulation of hepatic LDL receptors and increased clearance of LDL particles from the bloodstream.

Side Effects

Adverse reactions may occur with ezetimibe therapy.

Common Side Effects

  • Abdominal pain
  • Diarrhea
  • Fatigue
  • Headache
  • Nausea
  • Muscle pain

Serious or Rare Side Effects

  • Hepatitis or severe liver injury
  • Rhabdomyolysis, especially when combined with statins
  • Severe allergic reactions (e.g., angioedema, anaphylaxis)
  • Cholestatic jaundice
  • Pancreatitis
  • Myopathy with marked CK elevation

Precautions & Warnings

  • Before initiating therapy, several safety considerations are recommended.
  • Monitor liver function: obtain baseline hepatic enzymes and repeat periodically.
  • Assess baseline lipid profile: document LDL‑C levels prior to treatment.
  • Use with statins cautiously: consider dose adjustments and monitor for muscle toxicity.
  • Avoid in active liver disease: contraindicated in patients with unexplained persistent elevations of transaminases.
  • Pregnancy and lactation: only if potential benefit outweighs risk, as data are limited.
  • Store at room temperature: keep below 25 °C in the original packaging, protect from moisture and direct sunlight.

Avoid Interactions

Ezetimibe may interact with several medicines; awareness of interaction severity guides management.

Major Interactions (Avoid)

  • Cyclosporine: increases ezetimibe plasma concentrations.
  • Antifungal azoles (e.g., ketoconazole): may raise ezetimibe levels.
  • Bile‑acid sequestrants: reduce ezetimibe absorption when taken concurrently.

Moderate Interactions (Monitor Closely)

  • Statins: combined use can increase risk of myopathy; monitor CK.
  • Warfarin: possible alteration of INR; check coagulation status.
  • Niacin: may enhance risk of hepatic toxicity; monitor liver enzymes.

Frequently Asked Questions

Isovurex contains ezetimibe, a prescription medication indicated for lowering elevated low‑density lipoprotein cholesterol in adults with primary hyperlipidemia, heterozygous or homozygous familial hypercholesterolemia, and other related lipid disorders.

Ezetimibe inhibits the NPC1L1 transporter on the intestinal brush‑border, blocking the absorption of dietary and biliary cholesterol. This reduces the amount of cholesterol reaching the liver, leading to up‑regulation of hepatic LDL receptors and increased clearance of LDL‑C from the bloodstream.

The prescribed dose of Isovurex is determined by the treating physician based on the patient’s individual lipid profile, therapeutic goals, and any concomitant lipid‑lowering therapy. Dosing follows the approved labeling and should be individualized.

Safety data for ezetimibe in pregnancy and lactation are limited. It should be used only if the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by the prescriber in consultation with the patient.

To order Isovurex, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Statins inhibit hepatic HMG‑CoA reductase, whereas ezetimibe reduces intestinal cholesterol absorption. Both lower LDL‑C, and they can be used alone or together for additive effect. Ezetimibe is often considered when patients cannot tolerate high‑intensity statins or need additional LDL‑C reduction.

Isovurex should be stored at room temperature, below 25 °C, in its original packaging. Keep the product protected from moisture and direct sunlight, and store out of reach of children.

Isovurex is taken orally, typically once daily, with or without food, as directed by the prescriber. The tablet should be swallowed whole with a glass of water.

Serious but rare adverse events include hepatitis or severe liver injury, rhabdomyolysis (especially when combined with statins), severe allergic reactions such as angioedema, cholestatic jaundice, and pancreatitis. Patients should promptly report symptoms like jaundice, unexplained muscle pain, or rash.

Isovurex should be avoided in individuals with active liver disease, known hypersensitivity to ezetimibe or any excipients, and patients for whom cholesterol‑lowering therapy is contraindicated. The prescriber must assess each patient’s medical history before initiating therapy.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Ezetimibe

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT